Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
Less than half of all patients with aggressive non-Hodgkin's lymphoma (NHL) are cured with standard chemotherapy. Therefore, it is important to distinguish between responders to standard treatment and non-responders who may benefit from an early change to a more effective therapy. This study wa...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2002-09, Vol.13 (9), p.1356 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | 1356 |
| container_title | Annals of oncology |
| container_volume | 13 |
| creator | Spaepen, K Stroobants, S Dupont, P Vandenberghe, P Thomas, J de Groot, T Balzarini, J De Wolf-Peeters, C Mortelmans, L Verhoef, G |
| description | Less than half of all patients with aggressive non-Hodgkin's lymphoma (NHL) are cured with standard chemotherapy. Therefore, it is important to distinguish between responders to standard treatment and non-responders who may benefit from an early change to a more effective therapy. This study was intended to assess the value of a midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) scan to predict clinical outcome in patients with aggressive NHL.
Seventy newly diagnosed patients with aggressive NHL, who were treated with doxorubicin-containing chemotherapy, underwent a [(18)F]FDG-PET scan at midtreatment. Presence or absence of abnormal [(18)F]FDG uptake was related to progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier survival analysis. Multivariate analysis was performed to evaluate the effect of the International Prognostic Index (IPI) and early [(18)F]FDG-PET findings on PFS and OS.
At midtreatment, 33 patients showed persistent abnormal [(18)F]FDG uptake and none of these patients achieved a durable complete remission (CR), whereas 37 patients showed a negative scan; 31/37 remained in CR, with a median follow-up of 1107 days. Only 6/37 patients either achieved a partial response or relapsed. Comparison between groups indicated a statistically significant association between [(18)F]FDG-PET findings and PFS (P |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_12196360</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>12196360</sourcerecordid><originalsourceid>FETCH-LOGICAL-p122t-bc44af32bcc637887c0155e17afe85e19b78c4a3c14c8c2b7fd9ced230ea34d93</originalsourceid><addsrcrecordid>eNo1kMlOwzAYhH0A0VJ4BeQbcIjkJU3iI6paioTEBc6V4_xxDfEi2wHyFLwyEcvpG400M9KcoCURjBf1mpcLdJ7SKyGkEkycoQVlVFS8Ikv0tZVxmHCElKU2TuPgk8nROwzWpGRmkb31OspwnPCHyUd8g2lzuyv6YfTRd-A_Jz2MyifAIUJnVE7Yj1l5C9g4HGQ24GbvJyu1nqeSeQfsvCv2vtNvxl0nPEw2HL2VF-i0l0OCyz-u0Mtu-7zZF49P9w-bu8ciUMZy0aqylD1nrVIVr5umVoSu10Br2UMzU7R1o0rJFS1Vo1hb951Q0DFOQPKyE3yFrn57w9ha6A4hGivjdPh_hn8DTBRjXQ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Spaepen, K ; Stroobants, S ; Dupont, P ; Vandenberghe, P ; Thomas, J ; de Groot, T ; Balzarini, J ; De Wolf-Peeters, C ; Mortelmans, L ; Verhoef, G</creator><creatorcontrib>Spaepen, K ; Stroobants, S ; Dupont, P ; Vandenberghe, P ; Thomas, J ; de Groot, T ; Balzarini, J ; De Wolf-Peeters, C ; Mortelmans, L ; Verhoef, G</creatorcontrib><description><![CDATA[Less than half of all patients with aggressive non-Hodgkin's lymphoma (NHL) are cured with standard chemotherapy. Therefore, it is important to distinguish between responders to standard treatment and non-responders who may benefit from an early change to a more effective therapy. This study was intended to assess the value of a midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) scan to predict clinical outcome in patients with aggressive NHL.
Seventy newly diagnosed patients with aggressive NHL, who were treated with doxorubicin-containing chemotherapy, underwent a [(18)F]FDG-PET scan at midtreatment. Presence or absence of abnormal [(18)F]FDG uptake was related to progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier survival analysis. Multivariate analysis was performed to evaluate the effect of the International Prognostic Index (IPI) and early [(18)F]FDG-PET findings on PFS and OS.
At midtreatment, 33 patients showed persistent abnormal [(18)F]FDG uptake and none of these patients achieved a durable complete remission (CR), whereas 37 patients showed a negative scan; 31/37 remained in CR, with a median follow-up of 1107 days. Only 6/37 patients either achieved a partial response or relapsed. Comparison between groups indicated a statistically significant association between [(18)F]FDG-PET findings and PFS (P <1 x 10(-5)) and OS (P <1 x 10(-5)). In multivariate analysis, [(18)F]FDG-PET at midtreatment was a stronger prognostic factor for PFS (P <1 x 10(-7)) and OS (P <9 x 10(-6)) than the IPI (P <0.11 and P <0.03, respectively).
Early restaging [(18)F]FDG-PET may be used to tailor induction chemotherapy in patients with aggressive NHL.]]></description><identifier>ISSN: 0923-7534</identifier><identifier>PMID: 12196360</identifier><language>eng</language><publisher>England</publisher><subject>Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Child ; Child, Preschool ; Cyclophosphamide - administration & dosage ; Doxorubicin - administration & dosage ; Evaluation Studies as Topic ; Female ; Fluorodeoxyglucose F18 ; Humans ; Lymphoma, Non-Hodgkin - diagnostic imaging ; Lymphoma, Non-Hodgkin - drug therapy ; Lymphoma, Non-Hodgkin - mortality ; Lymphoma, Non-Hodgkin - pathology ; Male ; Middle Aged ; Monitoring, Physiologic - methods ; Multivariate Analysis ; Neoplasm Staging ; Predictive Value of Tests ; Prednisolone - administration & dosage ; Probability ; Prognosis ; Prospective Studies ; Sensitivity and Specificity ; Survival Rate ; Time Factors ; Tomography, Emission-Computed - methods ; Treatment Outcome ; Vincristine - administration & dosage</subject><ispartof>Annals of oncology, 2002-09, Vol.13 (9), p.1356</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12196360$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Spaepen, K</creatorcontrib><creatorcontrib>Stroobants, S</creatorcontrib><creatorcontrib>Dupont, P</creatorcontrib><creatorcontrib>Vandenberghe, P</creatorcontrib><creatorcontrib>Thomas, J</creatorcontrib><creatorcontrib>de Groot, T</creatorcontrib><creatorcontrib>Balzarini, J</creatorcontrib><creatorcontrib>De Wolf-Peeters, C</creatorcontrib><creatorcontrib>Mortelmans, L</creatorcontrib><creatorcontrib>Verhoef, G</creatorcontrib><title>Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description><![CDATA[Less than half of all patients with aggressive non-Hodgkin's lymphoma (NHL) are cured with standard chemotherapy. Therefore, it is important to distinguish between responders to standard treatment and non-responders who may benefit from an early change to a more effective therapy. This study was intended to assess the value of a midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) scan to predict clinical outcome in patients with aggressive NHL.
Seventy newly diagnosed patients with aggressive NHL, who were treated with doxorubicin-containing chemotherapy, underwent a [(18)F]FDG-PET scan at midtreatment. Presence or absence of abnormal [(18)F]FDG uptake was related to progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier survival analysis. Multivariate analysis was performed to evaluate the effect of the International Prognostic Index (IPI) and early [(18)F]FDG-PET findings on PFS and OS.
At midtreatment, 33 patients showed persistent abnormal [(18)F]FDG uptake and none of these patients achieved a durable complete remission (CR), whereas 37 patients showed a negative scan; 31/37 remained in CR, with a median follow-up of 1107 days. Only 6/37 patients either achieved a partial response or relapsed. Comparison between groups indicated a statistically significant association between [(18)F]FDG-PET findings and PFS (P <1 x 10(-5)) and OS (P <1 x 10(-5)). In multivariate analysis, [(18)F]FDG-PET at midtreatment was a stronger prognostic factor for PFS (P <1 x 10(-7)) and OS (P <9 x 10(-6)) than the IPI (P <0.11 and P <0.03, respectively).
Early restaging [(18)F]FDG-PET may be used to tailor induction chemotherapy in patients with aggressive NHL.]]></description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Doxorubicin - administration & dosage</subject><subject>Evaluation Studies as Topic</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Humans</subject><subject>Lymphoma, Non-Hodgkin - diagnostic imaging</subject><subject>Lymphoma, Non-Hodgkin - drug therapy</subject><subject>Lymphoma, Non-Hodgkin - mortality</subject><subject>Lymphoma, Non-Hodgkin - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monitoring, Physiologic - methods</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Staging</subject><subject>Predictive Value of Tests</subject><subject>Prednisolone - administration & dosage</subject><subject>Probability</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Sensitivity and Specificity</subject><subject>Survival Rate</subject><subject>Time Factors</subject><subject>Tomography, Emission-Computed - methods</subject><subject>Treatment Outcome</subject><subject>Vincristine - administration & dosage</subject><issn>0923-7534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMlOwzAYhH0A0VJ4BeQbcIjkJU3iI6paioTEBc6V4_xxDfEi2wHyFLwyEcvpG400M9KcoCURjBf1mpcLdJ7SKyGkEkycoQVlVFS8Ikv0tZVxmHCElKU2TuPgk8nROwzWpGRmkb31OspwnPCHyUd8g2lzuyv6YfTRd-A_Jz2MyifAIUJnVE7Yj1l5C9g4HGQ24GbvJyu1nqeSeQfsvCv2vtNvxl0nPEw2HL2VF-i0l0OCyz-u0Mtu-7zZF49P9w-bu8ciUMZy0aqylD1nrVIVr5umVoSu10Br2UMzU7R1o0rJFS1Vo1hb951Q0DFOQPKyE3yFrn57w9ha6A4hGivjdPh_hn8DTBRjXQ</recordid><startdate>200209</startdate><enddate>200209</enddate><creator>Spaepen, K</creator><creator>Stroobants, S</creator><creator>Dupont, P</creator><creator>Vandenberghe, P</creator><creator>Thomas, J</creator><creator>de Groot, T</creator><creator>Balzarini, J</creator><creator>De Wolf-Peeters, C</creator><creator>Mortelmans, L</creator><creator>Verhoef, G</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200209</creationdate><title>Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma</title><author>Spaepen, K ; Stroobants, S ; Dupont, P ; Vandenberghe, P ; Thomas, J ; de Groot, T ; Balzarini, J ; De Wolf-Peeters, C ; Mortelmans, L ; Verhoef, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p122t-bc44af32bcc637887c0155e17afe85e19b78c4a3c14c8c2b7fd9ced230ea34d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Doxorubicin - administration & dosage</topic><topic>Evaluation Studies as Topic</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Humans</topic><topic>Lymphoma, Non-Hodgkin - diagnostic imaging</topic><topic>Lymphoma, Non-Hodgkin - drug therapy</topic><topic>Lymphoma, Non-Hodgkin - mortality</topic><topic>Lymphoma, Non-Hodgkin - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monitoring, Physiologic - methods</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Staging</topic><topic>Predictive Value of Tests</topic><topic>Prednisolone - administration & dosage</topic><topic>Probability</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Sensitivity and Specificity</topic><topic>Survival Rate</topic><topic>Time Factors</topic><topic>Tomography, Emission-Computed - methods</topic><topic>Treatment Outcome</topic><topic>Vincristine - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Spaepen, K</creatorcontrib><creatorcontrib>Stroobants, S</creatorcontrib><creatorcontrib>Dupont, P</creatorcontrib><creatorcontrib>Vandenberghe, P</creatorcontrib><creatorcontrib>Thomas, J</creatorcontrib><creatorcontrib>de Groot, T</creatorcontrib><creatorcontrib>Balzarini, J</creatorcontrib><creatorcontrib>De Wolf-Peeters, C</creatorcontrib><creatorcontrib>Mortelmans, L</creatorcontrib><creatorcontrib>Verhoef, G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Spaepen, K</au><au>Stroobants, S</au><au>Dupont, P</au><au>Vandenberghe, P</au><au>Thomas, J</au><au>de Groot, T</au><au>Balzarini, J</au><au>De Wolf-Peeters, C</au><au>Mortelmans, L</au><au>Verhoef, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2002-09</date><risdate>2002</risdate><volume>13</volume><issue>9</issue><spage>1356</spage><pages>1356-</pages><issn>0923-7534</issn><abstract><![CDATA[Less than half of all patients with aggressive non-Hodgkin's lymphoma (NHL) are cured with standard chemotherapy. Therefore, it is important to distinguish between responders to standard treatment and non-responders who may benefit from an early change to a more effective therapy. This study was intended to assess the value of a midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) scan to predict clinical outcome in patients with aggressive NHL.
Seventy newly diagnosed patients with aggressive NHL, who were treated with doxorubicin-containing chemotherapy, underwent a [(18)F]FDG-PET scan at midtreatment. Presence or absence of abnormal [(18)F]FDG uptake was related to progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier survival analysis. Multivariate analysis was performed to evaluate the effect of the International Prognostic Index (IPI) and early [(18)F]FDG-PET findings on PFS and OS.
At midtreatment, 33 patients showed persistent abnormal [(18)F]FDG uptake and none of these patients achieved a durable complete remission (CR), whereas 37 patients showed a negative scan; 31/37 remained in CR, with a median follow-up of 1107 days. Only 6/37 patients either achieved a partial response or relapsed. Comparison between groups indicated a statistically significant association between [(18)F]FDG-PET findings and PFS (P <1 x 10(-5)) and OS (P <1 x 10(-5)). In multivariate analysis, [(18)F]FDG-PET at midtreatment was a stronger prognostic factor for PFS (P <1 x 10(-7)) and OS (P <9 x 10(-6)) than the IPI (P <0.11 and P <0.03, respectively).
Early restaging [(18)F]FDG-PET may be used to tailor induction chemotherapy in patients with aggressive NHL.]]></abstract><cop>England</cop><pmid>12196360</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2002-09, Vol.13 (9), p.1356 |
| issn | 0923-7534 |
| language | eng |
| recordid | cdi_pubmed_primary_12196360 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Child Child, Preschool Cyclophosphamide - administration & dosage Doxorubicin - administration & dosage Evaluation Studies as Topic Female Fluorodeoxyglucose F18 Humans Lymphoma, Non-Hodgkin - diagnostic imaging Lymphoma, Non-Hodgkin - drug therapy Lymphoma, Non-Hodgkin - mortality Lymphoma, Non-Hodgkin - pathology Male Middle Aged Monitoring, Physiologic - methods Multivariate Analysis Neoplasm Staging Predictive Value of Tests Prednisolone - administration & dosage Probability Prognosis Prospective Studies Sensitivity and Specificity Survival Rate Time Factors Tomography, Emission-Computed - methods Treatment Outcome Vincristine - administration & dosage |
| title | Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A33%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20restaging%20positron%20emission%20tomography%20with%20(%2018)F-fluorodeoxyglucose%20predicts%20outcome%20in%20patients%20with%20aggressive%20non-Hodgkin's%20lymphoma&rft.jtitle=Annals%20of%20oncology&rft.au=Spaepen,%20K&rft.date=2002-09&rft.volume=13&rft.issue=9&rft.spage=1356&rft.pages=1356-&rft.issn=0923-7534&rft_id=info:doi/&rft_dat=%3Cpubmed%3E12196360%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12196360&rfr_iscdi=true |